Bioxytran, Inc.
BIXT
$0.109
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.52M | 2.11M | 2.12M | 2.50M | 2.80M |
| Depreciation & Amortization | 7.80K | 7.90K | 8.80K | 9.10K | 9.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.97M | 2.23M | 2.75M | 3.39M | 3.84M |
| Operating Income | -1.97M | -2.23M | -2.75M | -3.39M | -3.84M |
| Income Before Tax | -2.92M | -2.14M | -2.68M | -3.44M | -4.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.92 | -2.14 | -2.68 | -3.44 | -4.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 13.30K | 26.60K | 35.10K | 69.90K | 70.70K |
| Net Income | -2.91M | -2.12M | -2.64M | -3.37M | -4.16M |
| EBIT | -1.97M | -2.23M | -2.75M | -3.39M | -3.84M |
| EBITDA | -1.96M | -2.22M | -2.75M | -3.38M | -3.83M |
| EPS Basic | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 484.77M | 559.38M | 614.02M | 624.07M | 576.27M |
| Average Diluted Shares Outstanding | 484.77M | 559.38M | 614.02M | 624.07M | 576.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |